Mark J. Levis, MD, PhD, Johns Hopkins University

Articles

Combining and Sequencing FLT3 Inhibitors in AML

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Progress in the Treatment of AML

July 20th 2020

Implications for Treating AML With CC-486

July 20th 2020

CC-486 Maintenance Therapy in AML

July 20th 2020

Gemtuzumab for AML

July 20th 2020

CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020

IDH Inhibitors and MDS

July 20th 2020

IDH1/2 Inhibitors for AML

July 20th 2020

IDH Mutations in AML

July 20th 2020

FLT3 Triplet Regimens for AML

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

July 20th 2020

Venetoclax in AML: Safety Profile

July 20th 2020

Optimal Use of Venetoclax in AML

July 20th 2020

VIALE Studies in AML

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

July 20th 2020

FLT3 Genetic Alterations in AML

July 20th 2020